A Phase 4 interventional study of Tranexamic acid and Physiologic saline in Hip Fractures, sponsored by Biogipuzkoa Health Research Institute. Not yet recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-05-17.
Sponsored by Biogipuzkoa Health Research Institute · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Tranexamic Acid in Hip Fractures — 2 open to participants now, 3 under way, none of them phase 3. Tranexamic Acid · Hip Fractures.
Among the 22 studies testing Tranexamic Acid in Hip Fractures, this one has the largest planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2023, is one of 9 in phase 4, and was the 21st registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →2 of the 22 studies testing Tranexamic Acid in Hip Fractures are open now, in 2 countries. Recruiting first, the newest first:
University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje · Sites in North Macedonia
Ages 65+
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 644 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 120 across the 21 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
Biogipuzkoa Health Research Institute is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Biogipuzkoa Health Research Institute has 1 study filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
2 of the studies testing Tranexamic Acid in Hip Fractures that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07432737University Hospital for Surgical Diseases St. Naum Ohridsk i- SkopjeOne Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures | 2027-05 |
| NCT03063892Gregory M Georgiadis MDEffect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing Tranexamic Acid in Hip Fractures, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Hip fracture in elderly patients is a pathology with a high economic and health impact on the patient himself and on the National Health System, especially considering the significant aging of the population of the Basque Country. Despite advances, hip fracture remains in the clinical groups with the highest in-hospital mortality. Hip fracture is associated with numerous adverse events and high mortality.
Numerous antifibrinolytics, such as tranexamic acid (TXA), have been used to limit bleeding in orthopedic surgery and thus prevent the need for blood transfusion. Numerous studies have shown that the use of tranexamic acid does not increase the risk of thrombosis.
It is proposed to carry out clinical research with drugs without commercial interest. A randomized, double-blind clinical trial to assess the efficacy of tranexamic acid in reducing blood loss in elderly patients with hip fracture.
Prevention and treatment of bleeding due to general or local fibrinolysis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Physiological saline
Other: Physiologic saline
Amchafibrin
Drug: Tranexamic acid
Physiological saline
Other: Physiologic saline
Amchafibrin
Drug: Tranexamic acid
Physiological saline
Other: Physiologic saline
Amchafibrin
Drug: Tranexamic acid
Physiological saline
Other: Physiologic saline
Amchafibrin
Drug: Tranexamic acid
Intravenous or topical administration
Placebo
Blood transfusion
Transfusion rate from patient admission to hospital discharge.
Time frame: From date of randomization until the date of hospital discharge, it is estimated to be day 3 post - operation.
Total blood loss
Time frame: From date of randomization until the date of hospital discharge, it is estimated to be day 3 post - operation.
Adverse events
Time frame: 3,6,9 and 12 months
Days at hospital
Time frame: From date of randomization until the date of hospital discharge, it is estimated to be day 3 post - operation.
Start is estimated for May 2023; primary completion for Jun 2024, 12 months later.
Of 33 non-industry phase 4 interventional studies under Hip Fractures, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 12 months is below that.
Counting every sponsor, half of 33 studies reached it within 25 months; a quarter within 11 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Biogipuzkoa Health Research Institute